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ABSTRACT 
 
Rational drug design is an area of science that evolves continuously in 
order to answer contemporary demands for a decrease in novel drug 
discovery turnover time. Multiple drug design modalities exist which 
may be exploited in response to the parameters of specific drug design 
projects. Bioisosteric modification of existing molecules and de novo 
design are two such approaches, both of which were employed in 
parallel in this study which aimed to compare their scope and 
efficiency using Tricyclic Antidepressants (TCAs) and Selective 
Serotonin Reuptake Inhibiting (SSRIs) molecules as case studies. 
Results indicated that bioisosterically modified structures did not have 
a higher affinity for their cognate receptor when compared to the 
template structure while the de novo design yielded molecules that 
were markedly different to the template from a structural perspective, 
and which also bound to the cognate receptor with an affinity superior 
to that of the template. This study showed therefore that bioisosteric 
modification is of utility when minor structural variations are 
considered sufficiently relative to a template molecule, and could 
consequently be of utility in the acquisition of new patents, in the 
reduction of toxicity, or in the attainment of improved biological 
profiles. It indicated furthermore, the role of the de novo approach in 
the successful exploration of novel pharmacophoric space and in the 
generation of molecular structures with an affinity significantly greater 
than that of lead molecules for a target receptor.  
 
Introduction: 
          Novel drug design is a challenging enterprise 
that is fraught with numerous pitfalls all of which delay the 
identification of clinically useful molecular structures1. 
Different rational drug design modalities exist, with their 
respective advantages and disadvantages. 
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 In the fragment based de novo design 
modality, the judicious planting of high affinity fragments at 
complementary loci within a druggable ligand binding 
pocket, allows their tethering in the simplest possible way  
 
 
 
such that the propensity to oral bioavailability is maximised, 
and the time to reach clinical trial phase is consequently 
shortened 2. Bioisosteric replacement also seeks to shorten 
drug discovery turn over time through the replacement of key 
molecular moieties with others of near equal molecular 
shapes and volumes and which also have common electronic 
distributions and physicochemical properties3. Two drug 
classes were taken as case studies – specifically the Selective 
Serotonin Reuptake Inhibitors (SSRIs) and the Tricyclic 
Antidepressants (TCAs). The pharmacophoric space probed 
was that of a series of bacterial transport proteins, and for 
each transport protein selected, de novo, and bioisosteric 
approaches were employed in parallel and the novel chemical 
structures generated through each were compared. The ligand 
binding pockets of the transport proteins were considered 
interesting from a drug design perspective owing to their 
reported roles in the absorption, distribution and elimination 
of endogenously produced and xenobiotic small molecules 4. 
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Materials and Methods:  
 Five Protein Data Bank5 (PDB) 
crystallographic depositions were selected for this study. Two 
of these described bacterial transport proteins bound to 
commonly used SSRIs, while another three described 
endogenous transporters (two bacterial and one human) 
bound to TCA small molecules in common use. Specifically, 
PDB IDs 3GWV6 and 3GWU6 describing the bound co-
ordinates of the SSRIs fluoxetine and sertraline  respectively, 
both complexed to leucine transporters (LeuT), PDB IDs 
2Q727 and 2Q6H7 describing the tricyclic molecules 
imipramine and clomipramine respectively, both bound to 
LeuT, and PDB ID 3APV8 describing amitriptyline bound to 
the transport protein human alpha1-acid glycoprotein, were 
recruited for this study. 
 Structure Activity Relationship (SAR) data 
obtained from the literature identified the moieties critical for 
binding for each small molecule considered9,10. For each 
crystallographic deposition considered, the respective small 
molecule ligand was extracted from its cognate ligand 
binding pocket. Molecular modelling was carried out using 
SYBYL®-X 1.211, SparkV10®12  was used for bioisosteric 
molecular generation and de novo design was carried out 
using LigBuilder® v1.213. In silico Ligand Binding Affinity 
(LBA) was calculated using X-SCORE® v1.314. 
 Bioisosteric novel molecular generation 
involved the identification and modification of loci on the 
template SSRI and TCA molecules other than those 
constituting the basic pharmacophoric scaffold, and which 
were considered important for binding. Specifically, 
molecular modification was user driven in SparkV10®12 at 
the loci described in Table 1. Molecular modification was 
carried out on one locus at a time. The algorithm embedded 
in SparkV10®12 supported the modification of these identified 
loci through the identification of fragments having similar 
electrostatic and steric properties to the ones singled out for 
modification from its fragment database. Termination of this 
process resulted in the generation of novel structures with 
bioisosterically modified groups at the predesignated 
molecular loci. These novel structures were ranked by the 
programme according to the Bio-Isostere Factor15 (BIF) % 
and Lipinski Rule16 compliance with the highest BIF%17 
denoting greatest similarity to the parent molecule. The 
SparkV10®12 algorithm also predicted which generated bio-
isosteric structures would be chemically unstable. These 
latter were eliminated from the bioisosterically generated 
pool of molecules. The five highest ranked (according to 
BIF%15) chemically stable structures generated through 
modification of each locus were selected, and modeled in 
SYBYL®-X 1.211 to ensure that these novel structures 
retained co-ordinates similar to those of the parent ligand. X-
SCORE® v1.314 was subsequently used in order to measure in 
silico LBA (pKd) of the parent small molecule and the five 
highest ranked bioisosterically modified structures obtained 
through each successive molecular replacement. The 
chemical moiety sustaining the highest BIF%15 for each 
stepwise bioisosteric substitution was identified and a single 
molecule bearing all of these substituents was modeled in 
SYBYL®-X 1.211 on the bound co-ordinates of the parent 
small molecule ligand. This molecule was exported to X-
SCORE® v1.314 and the in silico LBA calculated. 
 The de novo approach was carried out 
according to a methodology that was essentially opposite to 
that of the bioisosteric one. Specifically, bioisosteric design 
involved identifying and modifying those moieties that were 
considered critical to ligand binding in order to achieve a 
similar binding modality within a specific Ligand Binding 
Pocket (LBP). In the de novo approach, the moieties 
previously identified as critical to binding were retained in 
situ as seen in Table 1. These were computationally tethered 
together according to the genetic algorithm embedded in the 
grow and link options of LigBuilder® v1.213.  
 This process involved, for each ligand 
considered in this study, the creation of a number of seed 
structures (2-3 per small molecule) where the term seed 
implies the collection of fragments critical to ligand binding. 
These fragments were docked into the LBP at loci identical to 
those described in the crystallographic depositions selected as 
templates for this study. Seed creation was carried out in 
SYBYL®-X 1.211. Three dimensional maps, highlighting the 
polarity of the component loci of the LBPs of the receptors 
considered in this study were generated using the pocket 
algorithm of LigBuilder® v1.213.  
 
 
Table 1: Moieties selected for the TCA and SSRI molecules for bioisosteric replacement (highlighted in red) 
and the de novo approach (highlighted in blue) 
Bioisosteric replacement de novo design 
Imipramine 
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Clomipramine 
  
Amitriptyline 
 
 
Fluoxetine 
  
Sertraline 
  
 
  De novo growth was then sustained, in a user 
driven manner, within the confines of this delineated space 
using the grow (supports unidirectional molecular growth) 
and the link (allows the conjoining of separate molecular 
fragments) algorithms of LigBuilder® v1.213. The generated 
de novo structures were then organized into separate families 
with each family sharing an identical pharmacophoric 
scaffold, and ranked within each family according to LBA. 
This procedure was carried out using the process algorithm of 
LigBuilder® v1.213, which also gave information, for each 
novel molecule, regarding its general formula, logP and 
synthetic feasibility. This information allowed subsequent  
 
 
molecular analysis such that the de novo generated structures 
could be determined to be Lipinski Rule16 compliant or 
otherwise. 
 
Results and Discussions:  
Imipramine, clomipramine, amitriptyline, 
fluoxetine and sertraline were considered as template 
molecules. Each of these was modified at different molecular 
loci. The resultant bioisosterically modified structures (n=20 
derived from each parent molecule) were all compliant with 
Lipinski’s Rule of 516 and had a LBA (pKd) ranging from 
6.93 to 5.51. 
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These results are summarized in Table 2 which 
shows, for each parent molecule considered, the maximum 
and minimum LBA (pKd) obtained from the respective 
molecular cohort generated, together with the average 
recorded value. The LBA (pKd) of the parent molecule is 
included for comparison. 
 
Table 2: Maximum, minimum and average LBA 
(pKd) obtained for the generated bioisosteres, as 
calculated in X-SCORE® v1.3 
 
Graph 1 further amplifies this comparative 
exercise, and shows, of the molecular cohort generated from 
each parent molecule, the ratio between the bioisosterically 
generated structures whose LBA (pKd) was higher than that 
of the template resident small molecules and those whose 
LBA (pKd) was lower.  
The bioisosterically generated structures resulting 
from each successive modification exhibiting the highest 
BIF%15 scores were merged, when possible, using SYBYL®-
X 1.211, into a single molecular structure (designated as 
merged bioisostere in each case).  
 
 
Graph 1: Graph showing the number of generated 
bioisosteres that sustained an improvement in LBA 
(pKd) or otherwise 
 
 
Table 3 summarises the highest BIF%15 scoring 
molecules resulting from individual and merged bioisosteric 
modifications. The loci selected for modification are 
indicated as X, Y and Z. The LBA (pKd) score that resulted 
from each modification is once more included for all the 
resulting bioisosteres. The LBA (pKd) resulting from 
merging successive modification is highlighted in red.  
 
 
 
 
 
Table 3: Table showing the LBA (pKd) values of the highest BIF% scoring molecules of individual and 
merged bioisosteres 
 
 
X Y Z 
BIF
% 
LBA 
(pkd) 
 
Imipramine -C3H6NC2H6 / / N/A 6.2 
Bioisostere 1 -C6H13 / / 92 6.53 
 
Clomipramine -Cl -NCH3CH3 / N/A 6.23 
Bioisostere1 -Br -NCH3CH3 / 96 6.26 
Bioisostere2 -Cl -OCH3 / 94 6.14 
Merged 
bioisostere 
-Br -OCH3 / N/A 6.17 
Template molecules Generated bioisosteres 
Molecule LBA 
(pkd) 
Max  
LBA 
(pkd) 
Min  
LBA 
(pkd) 
Average  
LBA 
(pkd) 
Imipramine 6.20 6.53 6.06 6.22 
Clomipramine 6.23 6.40 6.07 6.23 
Amitriptyline 6.39 6.93 6.29 6.53 
Fluoxetine 5.79 6.33 5.51 5.79 
Sertraline 6.19 6.34 5.69 6.10 
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Amitriptyline -C2H4NC2H6 / / N/A 6.39 
Bioisostere1 -C5H11 / / 98 6.85 
 
Fluoxetine -CF3C6H4 -C6H6 -CH3 N/A 
5.79 
Bioisostere1 -SHC6H4 -C6H6 -CH3 94 
5.65 
Bioisostere2 -CF3C6H4 -C4H3S -CH3 92 
5.54 
Bioisostere3 -CF3C6H4 -C6H6 -Br 82 5.93 
Merged 
bioisostere 
-SHC6H4 -C4H3S -Br N/A 
5.52 
 
Sertraline -CH3 -C6H3Cl2 
/ N/A 
6.19 
Bioisostere1 -Br -C6H3Cl2 
/ 90 
6.34 
Bioisostere2 -CH3 -C6H3ClF 
/ 93 
5.91 
Merged 
bioisostere 
-Br -C6H3ClF 
/ N/A 
4.88 
 
In the de novo design phase of the study, 3 seed 
structures were generated for imipramine, amitriptyline and 
sertraline while 2 seed structures were generated for 
clomipramine and fluoxetine. 600 in silico novel structures 
were generated for imipramine, amitriptyline and sertraline 
while 400 in silico novel structures were identified for 
clomipramine and fluoxetine. Each molecular cohort 
generated was segregated by the process module of 
LigBuilder® v1.213 into families bearing similar 
pharmacophoric scaffolds. A total of 45, 32, 52, 42 and 49 
families were identified for imipramine, clomipramine, 
amitriptyline, fluoxetine and sertraline respectively. Within 
each family, molecules were listed in rank order of 
decreasing LBA (pKd). 10%, 26.5%, 16.2%, 70.5% and 
34.5% of the total number of de novo generated molecules for 
imipramine, clomipramine, amitritpyline, fluoxetine and 
sertraline respectively were identified as being Lipinski 
Rule16 compliant. 
These results are summarized in Table 4, which 
shows for each parent molecule considered, the maximum 
and minimum LBA (pKd) obtained from each de novo 
designed molecular cohort generated, together with the 
average recorded value. The LBA (pKd) of the parent 
molecule is included for comparison.  
Graph 2 compared, of the molecular cohorts 
generated from each parent molecule, the ratio between the in 
silico de novo generated structures whose LBA (pKd) was  
higher than that of the template resident small molecule and 
those whose LBA (pKd) was lower.  
 
 
 
 
Table 4: Maximum, minimum and average LBA 
(pKd) values measured for the generated de novo 
designed structures 
Template molecules Generated molecules 
Molecule LBA 
(pkd) 
Max 
LBA 
(pkd) 
Min 
LBA 
(pkd) 
Average 
LBA 
(pkd) 
Imipramine 6.20 9.80 7.08 7.65  
Clomipramine 6.23 8.36 6.16 7.06 
Amitriptyline 6.39 9.95 7.71 8.58 
Fluoxetine 5.79 7.26 5.83 6.22 
Sertraline 6.19 8.20 6.02 7.42 
 
Figures 1a-1e are a structural summary of these 
results. Each parent molecule, imipramine, clomipramine, 
amitriptyline, fluoxetine and sertraline together with the 
derived seeds, and the de novo in silico designed molecules 
which complied with Lipinski’s rules16 and exhibited the 
highest and lowest LBA (pKd) respectively are shown. 
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Graph 2: Graph showing the percentage of 
molecules that showed an improvement in the LBA 
(pKd) or otherwise 
 
 
 
Graph 3 compares the percentage improvement 
relative to each template small molecule with respect to LBA 
(pKd) when bioisosteric modifications and when de novo 
approach were adopted.  
 
Graph 3: Graph showing the percentage of 
molecules that showed an improvement in the LBA 
(pKd) when using the bioisosteric and de novo 
approaches 
 
 
Figure 1A: Imipramine template molecule, with its derived seeds and the top 3 de novo designed structures having the highest LBA (pKd) for each 
respective seed 
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Figure 1B: Clomipramine template molecule, with its derived seeds and the top 3 de novo designed structures having the highest 
LBA (pKd) for each respective seed 
 
 
 
Figure 1C: Amitriptyline template molecule, with its derived seeds and the top 3 de novo designed structures having the highest 
LBA (pKd) for each respective seed 
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Figure 1D: Fluoxetine template molecule, with its derived seeds and the top 3 de novo designed structures having the highest LBA 
(pKd) for each respective seed 
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Figure 1E: Sertraline template molecule, with its derived seeds and the top 3 de novo designed structures having the highest LBA 
(pKd) for each respective seed 
 
 
 
Discussion:  
                    The results obtained from this study were 
analysed against a scenario of a perceived necessity for a 
reduction in novel clinically viable drug turnover time. 
Consequently, the properties of the molecular cohorts 
obtained through the parallel implementation of bioisosteric 
modification and de novo in silico drug design were 
compared with an emphasis on LBA (pKd) and Lipinski 
Rule16 compliance.  
                    The SSRI and TCA template molecules selected 
for this study were identified from the PDB bound to 
different transport proteins. The nature of the bound transport 
protein was not considered to be critical for this study, owing 
to the fact that their importance was solely the provision of a 
rigid pharmacophoric space within which bioisosteric 
modification of their cognate bound small molecules and de 
novo design of novel structure from constructed seed 
molecules could be rationally sustained. 
 Comparison of the LBA (pKd) 
between the parent molecule, and the bioisosterically 
modified and the de novo designed molecular cohort was one 
of the cornerstones of this study. LBA (pKd) calculation of  
 
 
the parent molecules and the bioisosterically modified 
molecular cohort for their cognate receptor was carried out in 
X-SCORE® v1.314, while that of the de novo designed 
molecular cohort for the same transport proteins was carried 
out using LigBuilder® v1.213. The fact that both X-SCORE® 
v1.314 and LigBuilder® v1.213 were developed by the same 
workers, and that they share an identical algorithm for LBA 
(pKd) estimation facilitated this comparative exercise. 
                     A number of conclusions may be drawn from 
the data generated from this study. Analysis of the LBA 
(pKd) data shows that subsequent to bioisosteric molecular 
modification, no significant increases in LBA (pkK) are 
recorded. Reference is made to Tables 2 and 3 in which, it is 
evident that the average LBA (pKd) for the bioisosterically 
modified molecular cohort remains similar to that of the 
parent template ligands (Table 2) and where (Table 3) it may 
also be seen that merging the highest ranking BIF%15 
moieties from successive modifications also fails to increase 
the LBA (pKd) values. 
                        These results may be explained when the 
nature of bioisosteric modification is taken into account. 
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Bioisosteric modification is essentially, the exchange of one, 
or a group of atoms with others that are similar from an 
electronic and 3D volume perspective such that new 
molecules with biological activity similar to the parent are 
created17. The implication of this is that no significantly 
different atomic interactions will be forged by the 
bioisosterically modified structures and the receptor when 
compared to the parent molecule. Consequently, there should 
be no significant differences in the calculated LBA (pKd) 
between the novel and the parent structure.  
                       When the de novo approach was adopted, LBA 
(pKd) data differed markedly from that of the parent 
molecules, with significant increases being observed in all 
cases. Reference is made to Figures 1A – 1E in which the in 
silico calculated LBA (pKd) for the highest ranking ligands 
from the first 3 molecular families derived from each 
template molecule are compared.  
                       These results may also be explained when the 
modality of the de novo approach is considered. Here, the 
molecular moieties considered critical for binding were 
planted within the receptor LBP with novel molecular growth 
being allowed in non critical loci. This molecular growth was 
designed to ensure optimal interaction within the LBP, and 
also to completely occupy available space in the simplest way 
possible such that the number of interactions forged between 
the small molecule and the amino acids forming the LBP 
perimeter would be maximized without compromising 
Lipinski’s Rules16 from a molecular weight perspective18. 
This approach consequently allowed both for the 
identification of high affinity ligands, and also molecular 
innovation in a way that the bioisosteric approach, which is 
limited in the number of molecular moieties that could 
replace targeted loci (from an electronic and 3D volume 
perspective), could not sustain. In fact, a comparison of the 
molecular cohorts obtained through both approaches (refer to 
Table 3 and Figure 1A-1E) is indicative of the wider 
pharmacophoric space explored through the de novo 
approach. 
                          This study therefore practically illustrates 
and compares, the different thrust of the two drug design 
approaches both of which continue to play an important role 
in contemporary rational drug design processes. Bioisosteric 
replacement is a faster approach that does not contribute 
significantly to producing higher affinity ligands when 
compared to a lead molecule and consequently should not be 
the design modality of choice if a biological scenario of 
competitive inhibition is being envisaged. Neither should it 
be used if total innovation is being sought. It is however, 
relevant if small molecular changes are desired to acquire 
new patents or to achieve more favourable toxicity profiles, 
biological activity, or pharmacokinetics. The de novo 
approach, as demonstrated in this study, sustains both higher 
affinity with respect to a template lead structure and also 
innovation from a structural perspective. The implication is 
that it is relevant in the context of creating competitive 
inhibitors and also in the investigation of hitherto unexplored 
pharmacophoric space. The disadvantage from a drug design 
perspective could be an increased discovery turnover time 
owing to the increased requirement for clinical, toxicity and 
safety assessment.  
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